Potential New HIV Therapy Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Switchable CAR T-Cell System Shows Promise in Pancreatic Cancer Treatment
The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety. Read more.
4. The Growth of mHealth in Specialty Pharmacy
Mobile technology has helped to facilitate communication between pharmacists, patients, and their caregivers. Read more.
3. Amgen Will Cut Repatha List Price by 60%
Amgen will make evolocumab (Repatha) available at a list price of $5850, a 60% reduction from its annual list price of $14,100. Read more.
2. FDA Approves New Influenza Treatment
The approval marks the first new antiviral flu treatment with a novel mechanism of action backed by the agency in nearly 20 years. Read more.
1. NDA Submitted to FDA for Single-Tablet, 2-Drug HIV Treatment Regimen
Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection. Read more.
